IMW 2019 | MRD as a surrogate endpoint: what remains for FDA approval?

Faith Davies, Maria-Victoria Mateos and Nikhil Munshi

Faith Davies, MBBCh, MRCP, MD, FRCPath, from NYU Langone Medical Center, New York, NY, chairs a session at the International Myeloma Workshop (IMW) 2019, held in Boston, MA, with Maria-Victoria Mateos, MD, PhD, from University Hospital of Salamanca, Salamanca, Spain, and Nikhil Munshi, MD, from Dana-Farber Cancer Institute, Boston, MA. The speakers discuss what data the FDA need to be able to think about measurable residual disease (MRD) as a surrogate endpoint for progression-free survival.

Share this video